Marbocyl P 20 mg Tablets

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Ingredientes activos:

Marbofloxacin

Disponible desde:

Vetoquinol Ireland Limited

Código ATC:

QJ01MA93

Designación común internacional (DCI):

Marbofloxacin

Dosis:

20 mg/tablet

formulario farmacéutico:

Tablet

tipo de receta:

POM: Prescription Only Medicine as defined in relevant national legislation

Área terapéutica:

marbofloxacin

Estado de Autorización:

Authorised

Fecha de autorización:

2004-04-19

Ficha técnica

Health Products Regulatory Authority
28 August 2019
CRN00987J
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl P 20 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin 20 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet
Brown-beige spotted, circular divisible tablets.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Marbofloxacin tablet is indicated in the treatment of:
Skin and soft tissue infections (intertrigo, folliculitis, impetigo,
furunculosis, cellulitis) caused by susceptible strains.
Lower and upper urinary tract infections (UTI) associated or not with
prostatitis or epididymitis caused by susceptible strains.
Respiratory tract infections caused by susceptible strains.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredient. Do not use in dogs aged less than 12 months, or
less than 18 months for giant breeds of dogs.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Hypersensitivity (allergic) reactions may occur in treated animals.
Health Products Regulatory Authority
28 August 2019
CRN00987J
Page 2 of 4
At the therapeutic recommended dosage, no severe side-effects are to
be expected in dogs. Fluoroquinolones have been
shown to induce erosion of articular cartilage in juvenile dogs and
care should be taken to dose accurately, especially in young
animals. Mild side effects may occasionally occur such as vomiting,
softening of faeces, modification of thirst or transient
increase in activity. These signs cease spontaneously after treatment
and do not necessitate cessation of treatment.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Marbofloxacin may